|
Jun 23
|
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
|
|
Jun 20
|
Truist Initiates PTC Therapeutics (PTCT) Coverage with Buy Rating on Drug Launches
|
|
May 22
|
Those who invested in PTC Therapeutics (NASDAQ:PTCT) three years ago are up 51%
|
|
May 10
|
PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential
|
|
May 7
|
PTC Therapeutics: Q1 Earnings Snapshot
|
|
May 7
|
PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
May 6
|
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
|
|
May 6
|
PTC Therapeutics price target lowered to $57 from $65 at RBC Capital
|
|
May 5
|
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
|
|
May 5
|
PTC stock slides on new data for Huntington’s drug
|
|
May 5
|
PTC518 PIVOT-HD Study Achieves Primary Endpoint
|
|
Mar 20
|
PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies
|
|
Feb 24
|
Countdown to PTC Therapeutics (PTCT) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
|
|
Feb 20
|
PTC Therapeutics to Participate in Upcoming Investor Conferences
|
|
Feb 19
|
PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia
|
|
Feb 13
|
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
|
|
Oct 9
|
PTC Therapeutics Inc (PTCT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
|
Oct 9
|
PTC Therapeutics (PTCT) Surges 16.5%: Is This an Indication of Further Gains?
|
|
Oct 9
|
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
|
|
Oct 8
|
Sector Update: Health Care Stocks Rise Late Afternoon
|